7/102 sources · 2 publishersUpdated Nov 4, 12:58 UTC
H.C. Wainwright lifts Mirum Pharmaceuticals price target to $202
H.C. Wainwright raised its target price for Mirum Pharmaceuticals to $202 per share, up from $200. The adjustment follows the company's third‑quarter 2026 product sales of $185.7 million, a 40% year‑over‑year increase. The firm also reported LIVMARLI revenue of $133.4 million, up 45% YoY, and an 82% gross margin. Analysts note the higher target implies a substantial upside from the current market price.
Why it matters
The new target suggests investors could see a potential 132% gain from the latest closing price, according to the analyst note. The upgrade may attract additional buying interest in Mirum shares.
Key facts
- 1H.C. Wainwright increased its price target for Mirum Pharmaceuticals to $202 per diluted share, up from $200. investing.com
- 2The analyst also kept a Buy rating on the stock. tradingview.com
- 3Mirum reported third‑quarter 2026 net product sales of $185.7 million, a 40% increase year‑over‑year. investing.com
- 4LIVMARLI sales reached $133.4 million, up 45% year‑over‑year. investing.com
- 5The company posted a gross profit margin of 82% for the twelve‑month period. investing.com
- 6Quarterly earnings per share were a loss of $0.87. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.